贝瑞基因：全资子公司三代基因测序技术检测试剂盒获得医疗器械注册证

Core Viewpoint - Berry Genomics (000710.SZ) announced that its wholly-owned subsidiary, Hangzhou Berry Health and Technology Co., Ltd., has received a medical device registration certificate from the National Medical Products Administration for its α and β thalassemia gene testing kit, marking a significant breakthrough in the clinical application of third-generation sequencing technology [1] Group 1 - The gene testing kit utilizes single-molecule sequencing to qualitatively detect mutations in thalassemia genes from human peripheral venous whole blood samples [1] - The kit specifically identifies four deletions and three point mutations in the α-globin gene, as well as sixteen point mutations in the β-globin gene [1] - The acquisition of the registration certificate enhances the systematic layout of the company's "research - hardware - product" strategy, laying a product foundation for establishing a "Chinese solution" for third-generation sequencing [1]